ERG and prostate cancer: Ets overexpression may follow chromosome rearrangements, from copy gains of ETV1 in melanoma [23], to fusion of ERG or ETV1 to the TMPRSS2 promoter, resulting in androgen-inducible expression in prostate cancer [24], associated with aggressive disease [25].